Swipe Left For English News
1
引领绿色生物药发展，技术创新赋能健康未来
2
为全行业提供端到端绿色生物药解决方案
上海,
2024年12月11日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司的绿色生物药解决方案（Green CRDMO），成功入选联合国全球契约组织（UNGC）“‘二十年二十佳’企业可持续发展案例”报告并受邀参加全球路演。药明生物将致力于在打造一个更健康未来的征途中，持之以恒、不懈努力。
2024年是联合国全球契约组织提出ESG（环境、社会和公司治理）理念和原则的二十周年，值此之际，联合国全球契约组织发起了ESG+20系列活动。其中，“‘二十年二十佳’企业可持续发展案例”报告是系列活动中的重要一环，旨在分享ESG领域中的最佳实践案例，以此展现企业在可持续发展变革道路上的贡献，并在全球范围内传播和推广可持续发展的新思路与新举措。
桑达·奥佳博
联合国助理秘书长
UNGC总干事
在联合国全球契约引入环境、社会与治理（ESG）概念20周年之际，以及即将迎来的联合国全球契约25周年之际，我们的在华联络办公室特别策划了面向中国企业的可持续发展案例征集活动。这些企业独特之处在于，在追求经济发展的同时，彰显了其对可持续发展的独特承诺。这些案例不仅展现了中国企业在经济效益、创新能力和包容性发展方面的成就，更凸显了他们在平衡社会责任、环境保护与经济增长方面所付出的努力。通过多样化的可持续发展战略，这些企业推动了绿色技术的应用、负责任的资源使用和社区发展，丰富了中国经济的可持续性内涵，并为全球可持续发展目标提供了宝贵的经验和见解。
陈智胜博士
首席执行官
ESG委员会主席
药明生物
我们非常荣幸能够入选这份报告，这彰显了公司独树一帜的CRDMO商业模式，以及始终坚守可持续发展承诺的决心。作为绿色生物药解决方案领域的全球领导者，我们持续追求ESG卓越表现，同时一如既往为全球合作伙伴提供绿色研发、绿色开发以及绿色生产的创新端到端解决方案。展望未来，我们将持续携手各方，共同推动整个价值链向更加负责任的实践迈进。
作为联合国全球契约组织的积极参与者，药明生物致力于驱动绿色生物制药技术创新，不断提升运营效率，为全面践行联合国可持续发展目标贡献力量。公司将绿色技术融入研发、开发和生产流程中，包括自主研发的WuXiBody™双特异性抗体技术平台、WuXiUI™超强化分批补料生物工艺平台和WuXiUP™超高效连续细胞培养生产工艺平台、以及一次性生产技术（SUT）。这些技术平台和工艺能够加快研发进程，提高生产效率，同时减少资源和能源消耗及废弃物产生，显著降低碳足迹，最小化生物药全生命周期的环境影响。
近年来，药明生物在可持续发展领域的战略和举措取得了长足进展，并赢得了业界广泛认可：连续两年获得明晟（MSCI）最高AAA ESG评级；入选标普道琼斯可持续发展世界指数和标普道琼斯新兴市场指数；获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业；跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-；入选富时社会责任指数系列；入选恒生ESG 50指数，充分彰显了公司在可持续发展领域的卓越表现。
扫描下图中二维码或点击原文链接下载报告
关于联合国全球契约组织
联合国全球契约组织总部位于美国纽约联合国总部，隶属于联合国秘书处，是全球最大的企业可持续发展倡议。自2000年由时任联合国秘书长科菲·安南发起创立以来，致力于携手企业界“为全球市场带来更加人性化的面孔”，帮助全球公司实施责任商业战略和实践，推动联合国《2030年议程》的实现。
成立至今，联合国全球契约组织在全球170多个国家拥有超过20,000 家会员企业及利益相关方。
联合国全球契约组织从2017年在中国设立联络直属联络办公室，在中国运营以来，越发坚定地相信，中国企业和在华跨国公司正以其独特的贡献成为促进人类和地球可持续发展的积极力量。作为世界上最大的发展中国家，中国不仅是涵盖全球500强企业数量最多的国家(2023年中国共有142家公司上榜)，而且是4,400多万中小型企业的注册地。中国国内经济、海外投资和贸易的规模巨大，关乎数十亿人的福祉和地球的可持续发展。
截至2024年7月，联合国全球契约组织在华联络办公室的中国会员企业已超过1100家，涵盖了各行各业，在华为企业量身打造三大加速器项目：气候雄心企业加速器项目（Climate Ambition Accelerator，CAA）、性别平等目标企业加速器项目（Target Gender Equality, TGE）、青年专业人才SDG创新加速器项目，并通过气候变化、零碳转型、性别平等、供应链产业链韧性、可持续发展商业创新、道路安全与可持续交通、一带一路可持续发展等可持续发展主题活动，助力中国企业迈向可持续发展未来。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
1
Leading Green CRDMO Driven by Innovation for a Healthier Future
2
Offering End-to-end Green Biologics Solutions for the Entire Industry
Shanghai,
December 11, 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the "20 Case Examples for 20 Years: Private Sector's Sustainable Development in China" report initiated by the United Nations Global Compact. The company has been invited to UNGC global roadshow and has earned recognition for its effective and dedicated efforts to continue the advancement of green biologics solutions for a healthier future.
The year 2024 marks the 20th anniversary of the ESG (Environmental, Social and Governance) concept put forward by the UN Global Compact, and a series of ESG+20 celebration activities have been launched, with the "20 Case Examples for 20 Years: Private Sector's Sustainable Development in China" report being a crucial component. The report aims to showcase best practices in ESG as a way to reveal contributions by companies successful in sustainability development transformation, as well as to share their innovative ideas and actions with the world.
Sanda Ojambo
Assistant Secretary-General
United Nations Global Compact
On the occasion of the 20th anniversary of the introduction of the ESG (Environmental, Social and Governance) concept by the UN Global Compact, and the upcoming 25th anniversary of the UN Global Compact, our China Liaison Office has specially curated sustainability case studies from enterprises in China. These companies are distinctive in that, while pursuing economic development, they reflect their unique commitment to sustainable development. These cases not only highlight the economic efficiency, innovation and inclusivity of Chinese enterprises but showcase their efforts to balance social responsibility, environmental protection and economic growth. Through diverse sustainable development strategies, these enterprises promote the application of green technologies, responsible resource usage and community development, enriching the sustainability connotation of the Chinese economy and providing valuable experience and insights for global sustainable development goals.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are honored to be included in the UN Global Compact report, which showcases our distinctive business model and the firm commitment to pursuing sustainable development. As a global leader in Green CRDMO, we continuously strive to deliver our own ESG excellence, while remaining dedicated to enabling global partners with end-to-end green biologics solutions driven by innovation — from green research, green development, to green manufacturing. Going forward, we will keep pushing industry boundaries, jointly working with all stakeholders to promote responsible practices throughout the whole value chain.
As a participant of the UN Global Compact, WuXi Biologics actively drives innovation and operational efficiency through green technology, and continuously makes contributions towards the United Nations Sustainable Development Goals. The company integrates green technology into its research, development, and manufacturing processes. In particular, it boasts of the proprietary universal bispecific antibody platform WuXiBody™ for green research; ultra-intensified fed-batch production platform WuXiUI™ and ultra-high productivity continuous processing platform WuXiUP™ for green development; and Single-Use Technology for green manufacturing. These technology platforms and processes can expedite timelines and increase productivity, while at the same time minimizing carbon footprint and end-of-life environmental impact through significant reductions in resource and energy consumption, and waste generation.
Over the past several years, WuXi Biologics has earned a number of recognitions for its significant progress in pursuing sustainable development. It was granted an AAA rating from MSCI ESG Ratings for two consecutive years; included in the DJSI World Index and Emerging Markets Index; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.
About the United Nations Global Compact Liaison Office in China
Since the establishment of the United Nations Global Compact Liaison Office in China in 2017, we have become increasingly convinced that Chinese enterprises and multinational companies operating in China are a positive force in advancing sustainable development for the planet at large.
As the world's largest developing country, China not only boasts the most Fortune Global 500 companies (with 142 companies listed in 2023) but also hosts over 44 million small and medium-sized businesses. The sheer scale of China's domestic economy, overseas investments and trade significantly influence the well-being of billions of people and the progress of sustainable development worldwide, underscoring the magnitude and importance of our collective work.
The United Nations Global Compact Liaison Office in China, with over 1,100 participants from various industries as of July 2024, tailors four major accelerator programmes for these participants: the Climate Ambition Accelerator (CAA), the Target Gender Equality (TGE), the SDG Innovation Accelerator for Young Professionals (SDGI) and the SDG Ambition Accelerator (SDGA).
Through programmes and events focused on climate change, zero-carbon transition, gender equality, supply chain resilience, sustainable business innovation, Sustainable Infrastructure for the Belt and Road Initiative to accelerate the SDGs, Sino-Africa Corporate Community Action Network on Sustainable Development and Global Development Initiative for SDGs Pilot Projects, we help to foster innovative and action-driven partnerships and support our Chinese participants to move towards a sustainable future along with partners from all over the world.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
